Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Racial and Gender Disparities in Clinical Trial Representation for Age-Related Macular Degeneration Treatments: A Scoping Review

Title: Racial and Gender Disparities in Clinical Trial Representation for Age-Related Macular Degeneration Treatments: A Scoping Review
Authors: Amirmohammad Shafiee; Taylor Juran; Iza Zabaneh; Deepkumar Patel; Karen Allison
Source: Journal of Clinical & Translational Ophthalmology ; Volume 3 ; Issue 3 ; Pages: 16
Publisher Information: Multidisciplinary Digital Publishing Institute
Publication Year: 2025
Collection: MDPI Open Access Publishing
Subject Terms: age-related macular degeneration; vascular endothelial growth factor; blindness; clinical trials
Description: Background/Objective: Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy is the primary treatment for neovascular AMD. This study aimed to assess racial, ethnic, and gender representation in U.S.-based randomized controlled trials (RCTs) of anti-VEGF therapies. Methods: A systematic PubMed search identified 19 eligible RCTs. Titles and abstracts were screened, and demographic data were independently extracted and cross-verified. Chi-squared analysis was used to evaluate disparities in participant representation. Risk of bias was assessed using the ROBIS checklist. Results: Among 8003 participants across 19 trials, 92.3% were Caucasian. Asian, African American, Hispanic/Latino, and American Indian participants collectively comprised just over 5%. This underrepresentation of non-Caucasian groups was statistically significant (p < 0.01, df = 4) and not associated with study sponsorship. Gender analysis showed 59% female and 41% male participation, which was not statistically significant (p = 0.83, df = 1). Conclusions: Non-Caucasian populations remain significantly underrepresented in anti-VEGF RCTs for AMD. This raises concerns about the generalizability of trial findings to diverse populations. Future clinical trials must prioritize inclusive recruitment to ensure equitable, evidence-based care for all patients.
Document Type: text
File Description: application/pdf
Language: English
Relation: https://dx.doi.org/10.3390/jcto3030016
DOI: 10.3390/jcto3030016
Availability: https://doi.org/10.3390/jcto3030016
Rights: https://creativecommons.org/licenses/by/4.0/
Accession Number: edsbas.56266EBE
Database: BASE